Biocryst Pharmaceuticals to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, England.

Back to news